Yasmine Wasfi - Concepedia

Author

Yasmine Wasfi

Janssen (United States)

Also Known As

Y Wasfi, Y. S. Wasfi, Y. Wasfi, YASMINE S WASFI, Yasmine S Wasfi, Yasmine S. Wasfi, Yasmine Wasfi

Publications

4.3K

Citations

H-Index

Concepts

All Affiliations

Janssen (United States)Dermatologikum Hamburg Probity Medical Research Oregon Medical Research Center The University of Melbourne

About

Yasmine Wasfi is an author at Janssen (United States) specializing in medicine, asthma, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	124
2	Health Sciences	1	1	14
3	Applied Physiology	1	1	14
4	Epidemiology	1	1	79
5	Exercise Physiology	1	1	14

Yasmine Wasfi

Publications

3.8K

Citations

H-Index

Page 1

	Year	Citations
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial Andrew Blauvelt, Kim Papp, C.E.M. Griffiths, Journal of the American Academy of Dermatology	2017	838
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator–controlled VOYAGE 2 trial Kristian Reich, April W. Armstrong, Peter Foley, Journal of the American Academy of Dermatology	2017	712
Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double‐blind, phase <scp>III NAVIGATE</scp> trial Richard G. Langley, Tsen‐Fang Tsai, Susan Flavin, British Journal of Dermatology	2017	336
Guselkumab (an IL-23–specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis Howard Sofen, Stacy Smith, Robert Matheson, Journal of Allergy and Clinical Immunology	2014	298
A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis Kenneth B. Gordon, Kristina Callis Duffin, Robert Bissonnette, New England Journal of Medicine	2015	291
Long‐term efficacy of ustekinumab in patients with moderate‐to‐severe psoriasis treated for up to 5 years in the PHOENIX 1 study Alexa B. Kimball, Kim Papp, Yasmine Wasfi, Journal of the European Academy of Dermatology and Venereology	2012	209
Long‐term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate‐to‐severe psoriasis: results from the PHOENIX 2 study through 5 years of follow‐up Richard G. Langley, Mark Lebwohl, Gerald G. Krueger, British Journal of Dermatology	2014	201
Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions Peter Foley, Kenneth B. Gordon, C.E.M. Griffiths, JAMA Dermatology	2018	117
Ustekinumab improves nail disease in patients with moderate‐to‐severe psoriasis: results from <scp>PHOENIX</scp> 1 Phoebe Rich, Marc Bourcier, Howard Sofen, British Journal of Dermatology	2013	110
The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection Tsen‐Fang Tsai, Vincent Ho, Michael Song, British Journal of Dermatology	2012	94

Page 1